MANAGEMENT OF HEARING LOSS IN A PATIENT WITH MULTIDRUG-RESISTANT TUBERCULOSIS (MDR-TB)

I Gusti Ayu Mahaprani Danastri; Ketut Tadeus Max Nurcahya Pinatih

doi:10.14710/dmj.v15i6.54140

DOI: https://doi.org/10.14710/dmj.v15i6.54140

MANAGEMENT OF HEARING LOSS IN A PATIENT WITH MULTIDRUG-RESISTANT TUBERCULOSIS (MDR-TB)

I Gusti Ayu Mahaprani Danastri - Otorhinolaryngology and Head-Neck Surgery Department, Faculty of Medicine, Universitas Udayana, Denpasar, Indonesia, Indonesia

*Ketut Tadeus Max Nurcahya Pinatih - Otorhinolaryngology and Head-Neck Surgery Department, Faculty of Medicine, Universitas Udayana, Denpasar, Indonesia, Indonesia

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Citation Format:

Abstract

Background: Multidrug-resistant tuberculosis (MDR-TB) remains a major global health concern requiring prolonged treatment with second-line drugs. Aminoglycosides such as kanamycin are still widely used but carry a high risk of ototoxicity that may result in permanent hearing loss. Case Presentation: We report a 39-year-old female with rifampicin-resistant pulmonary tuberculosis who developed bilateral progressive hearing loss after two weeks of kanamycin therapy. Otoscopy and tympanometry were normal, but otoacoustic emission (OAE) showed bilateral refer results. Pure tone audiometry revealed severe bilateral sensorineural hearing loss. Kanamycin was discontinued and replaced by an injection-free regimen, and the patient was fitted with bilateral hearing aids to support communication. Conclusion: This case emphasizes the importance of baseline and regular audiological monitoring during MDR-TB treatment to detect early ototoxic effects and to allow prompt regimen modification to minimize permanent disability.

Fulltext View|Download Email colleagues

Keywords: aminoglycoside; audiology; hearing loss; ototoxicity; tuberculosis

Funding: Universitas Udayana

Article Metrics:

Article Info

Section: Case Report

Language : EN

In Vol 15, No 6 (2026): JURNAL KEDOKTERAN DIPONEGORO (DIPONEGORO MEDICAL JOURNAL)

WHO. Global Tuberculosis Report 2022. Geneva: World Health Organization; 2022
Dillard LK, Manji I, Huang L, et al. Prevalence of aminoglycoside-induced hearing loss in drug-resistant tuberculosis patients: a systematic review. J Infect. 2021;83:27-36
Heysell SK, Ahmed S, Rahman MT, et al. Hearing loss with kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh. Eur Respir J. 2018;51(3):1701778
Campbell KCM, Le Prell CG. Drug-induced ototoxicity: diagnosis and monitoring. Drug Saf. 2018;41(5):451-64
Rybak LP, Ramkumar V. Ototoxicity. Kidney Int. 2007;72(8):931-5
Xie J, Talaska AE, Schacht J. New developments in aminoglycoside therapy and ototoxicity. Hear Res. 2011;281(1-2):28-37
Putra ON, Hidayat F, Sagitha I. Ototoxicity in multidrug-resistant tuberculosis: a scoping review of the Indonesian studies. J Pharm Sci. 2022;5(1):62-73
Harris T, Soraya B, Simon SH, et al. Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients. S Afr Med J. 2012;102(6):363-6
Sagwa EL, Kappen JV, Gerritsen A, et al. Comparing amikacin and kanamycin-induced hearing loss in MDR-TB treatment programmes in Namibia. BMC Pharmacol Toxicol. 2015;16:27
Yulianti SM, Sally M. Hearing impairment in multidrug-resistant tuberculosis patients. Otorhinolaryngol Indones. 2015;45(2):83-9
Prezant TR, Agapian JV, Bohlman MC, et al. Mitochondrial mutations associated with aminoglycoside ototoxicity. N Engl J Med. 1993;329(15):1091-6
Van der Watt JJ, Wilkinson KA, et al. High prevalence of hearing loss in MDR-TB patients in South Africa not routinely monitored. Int J Tuberc Lung Dis. 2015;19(7):744-9
West N, Gadkowski LB, et al. Early audiology referral improves detection of ototoxicity in MDR-TB therapy. Clin Infect Dis. 2019;68(12):2005-12
Garinis AC, Feeney MP, et al. Monitoring approaches for ototoxicity detection in clinical trials. J Am Acad Audiol. 2017;28(9):758-69
Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382:893-902
Khoza-Shangase K, et al. Hearing aid provision in TB ototoxicity: clinical outcomes. Int J Audiol. 2017;56(10):804-11
Le Prell CG, Yamashita D, et al. Mechanisms and prevention of drug-induced hearing loss. Audiol Neurootol. 2011;16(3):149-70
Mukherjee A, et al. Antioxidant therapy in aminoglycoside ototoxicity: clinical perspectives. Front Cell Neurosci. 2022;16:823456
Swanepoel DW, et al. Ototoxicity monitoring in resource-limited settings. Bull World Health Organ. 2020;98(9):601-9
Faye LM, et al. Hearing impairment among drug-resistant tuberculosis patients in Eastern Cape, South Africa. Int J Environ Res Public Health. 2025;22(5):810

Last update:

No citation recorded.

Last update:

No citation recorded.

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Authors who publish with this journal agree to the following terms: - Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC-BY-NC-SA) that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal. - Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal. - Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).